Celgene multiple likely to expand further, says Cantor

theflyonthewall.com

Cantor believes that Celgene is in the process of diversifying its revenue as it introduces new products. The firm has an upbeat outlook on the company's Apremilast drug and keeps a Buy rating on the stock.

Rates

View Comments (0)